{"id":26661,"date":"2022-11-02T16:48:39","date_gmt":"2022-11-02T20:48:39","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=26661"},"modified":"2024-08-15T15:31:18","modified_gmt":"2024-08-15T19:31:18","slug":"elizabeth-a-mittendorf-m-d-ph-d","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d","title":{"rendered":"Elizabeth A. Mittendorf, MD, PhD"},"content":{"rendered":"\n<p>Immunotherapy has revolutionized the management of patients&nbsp;diagnosed with triple&nbsp;negative breast cancer (TNBC), with anti-PD-1 checkpoint blockade&nbsp;now standard in the&nbsp;first-line setting for metastatic, PD-L1-positive TNBC, and&nbsp;in the neoadjuvant (pre-surgical) setting in combination with chemotherapy for&nbsp;early-stage TNBC regardless of&nbsp;PD-L1 status. In the latter setting, some&nbsp;patients might not need immunotherapy to&nbsp;respond though, and determining who could&nbsp;spare them from possible side effects. This&nbsp;is the question that Dr. Elizabeth Mittendorf&nbsp;is investigating in the Neo-TRIBUTE&nbsp;(Translational Resource for Immuno-Biology&nbsp;to Understand Therapeutic Efficacy) clinical&nbsp;trial.<br><br>By utilizing multiplex tissue imaging and biospecimens obtained&nbsp;from blood, tissue, and&nbsp;stool before and throughout treatment, Dr. Mittendorf\u2019s&nbsp;team hopes to gain a better&nbsp;understanding of how immunotherapy influences&nbsp;tumor-infiltrating and circulating&nbsp;immune cells as well as how spatial&nbsp;organization of immune cells is associated with&nbsp;response to therapy. Ultimately,&nbsp;they hope to identify composite biomarkers that reflect&nbsp;the tumor, the&nbsp;microenvironment, and patient\u2019s systemic immune status that predicts&nbsp;who is&nbsp;likely to benefit from adding immunotherapy to chemotherapy as well as those&nbsp;most&nbsp;likely to experience toxicity, in order to improve care in the clinic.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">NeoTRIBUTE Clinical Trial<\/h3>\n\n\n\n<p>Dana-Farber Cancer Institute | Breast Cancer | 2022<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">An Exploratory Biomarker Study of Metastatic Triple-Negative Breast Cancer Patients Treated with Atezolizumuab, an Anti-PD-L1 Antibody, and nab-Paclitaxel (TRIBUTE)<\/h3>\n\n\n\n<p>Dana-Farber Cancer Institute | Breast Cancer | 2019<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immunotherapy has revolutionized the management of patients&nbsp;diagnosed with triple&nbsp;negative breast cancer (TNBC), with anti-PD-1 checkpoint blockade&nbsp;now standard in the&nbsp;first-line setting for metastatic, PD-L1-positive TNBC, and&nbsp;in the neoadjuvant (pre-surgical) setting in combination with [&hellip;]<\/p>\n","protected":false},"featured_media":27501,"template":"","tax_cancer_type":[450],"tax_grant_type":[483],"tax_award_year":[479],"tax_institutions":[495],"tax_location_states":[490],"class_list":["post-26661","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"Grantee","quote":"","scientist_last_name":"Mittendorf","show_on_landing":true,"scientist_publish_until":"20250430"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elizabeth A. Mittendorf, MD, PhD - Cancer Research Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elizabeth A. Mittendorf, MD, PhD - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"Immunotherapy has revolutionized the management of patients&nbsp;diagnosed with triple&nbsp;negative breast cancer (TNBC), with anti-PD-1 checkpoint blockade&nbsp;now standard in the&nbsp;first-line setting for metastatic, PD-L1-positive TNBC, and&nbsp;in the neoadjuvant (pre-surgical) setting in combination with [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-15T19:31:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"571\" \/>\n\t<meta property=\"og:image:height\" content=\"571\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d\",\"name\":\"Elizabeth A. Mittendorf, MD, PhD - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg\",\"datePublished\":\"2022-11-02T20:48:39+00:00\",\"dateModified\":\"2024-08-15T19:31:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg\",\"width\":571,\"height\":571},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elizabeth A. Mittendorf, MD, PhD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elizabeth A. Mittendorf, MD, PhD - Cancer Research Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d","og_locale":"es_ES","og_type":"article","og_title":"Elizabeth A. Mittendorf, MD, PhD - Cancer Research Institute","og_description":"Immunotherapy has revolutionized the management of patients&nbsp;diagnosed with triple&nbsp;negative breast cancer (TNBC), with anti-PD-1 checkpoint blockade&nbsp;now standard in the&nbsp;first-line setting for metastatic, PD-L1-positive TNBC, and&nbsp;in the neoadjuvant (pre-surgical) setting in combination with [&hellip;]","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d","og_site_name":"Cancer Research Institute","article_modified_time":"2024-08-15T19:31:18+00:00","og_image":[{"width":571,"height":571,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d","name":"Elizabeth A. Mittendorf, MD, PhD - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg","datePublished":"2022-11-02T20:48:39+00:00","dateModified":"2024-08-15T19:31:18+00:00","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg","width":571,"height":571},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/elizabeth-a-mittendorf-m-d-ph-d#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Elizabeth A. Mittendorf, MD, PhD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/11\/Mittendorf.jpg","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/26661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/27501"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=26661"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=26661"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=26661"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=26661"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=26661"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=26661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}